SLN
Silence Therapeutics plcPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 Silence Therapeutics reported a significant year-over-year decline i…
- Jun 29 to Jul 6 ▼ 5 days of insider sells: $0.00 by 1 insider
- Aug 10 ▼ 1 insider sell $0.00
- Aug 10 ▼ Silence Therapeutics is conducting a $150M underwritten public offer…
- Aug 10 ▲ Silence Therapeutics announced positive topline Phase 2 SANRECO tria…
- Aug 14 ▼ Short interest jumps 32.4% to 2.43M
- Oct 19 ▲ Silence Therapeutics plc entered into a definitive agreement to be a…
- Oct 19 Trading halt: Trading Halt: SLN, T1 (News Pending)
- Oct 19 ▲ Silence Therapeutics plc has entered into a definitive agreement to…
- Oct 19 ▲ Silence Therapeutics announced a definitive agreement to be acquired…
- Oct 19 Trading halt: Halt Resumed: SLN, trading resumed after T3 (News and Resu…
- Oct 21 ▼ HC Wainwright & Co. downgrades
Signal stack
Where each data set points today.
- InsidersMIXED
No open-market sales.
- InstitutionsBULLISH
Q3 2026: 20 added (1 new), 3 trimmed or exited. Largest new: Fmr $51.5M.
- Short sellersCOVERING
Short interest −17.4% to 2.42M shares. 1.0 days to cover, ≈3.9% of shares.
- TrendUPTREND
34% above its 50-day average. New closing high $19.83 on Nov 13.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | NEW | $51.5M |
| MORGAN STANLEY | DOUBLED | $19.2M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $12.8M |
| Qube Research & Technologies Ltd | DOUBLED | $11.6M |
| UBS Group AG | DOUBLED | $6.7M |
| BlackRock, Inc. | ADD | $3.6M |
| BARCLAYS PLC | DOUBLED | $2.1M |
| JANE STREET GROUP, LLC | TRIM | $2.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Oct 2026Price is inside the target range. Median implies +1%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Aug 11, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Jun 24, 2026 | Cantor Fitzgerald INITIATE | Overweight |
| Jun 17, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 605,174 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 100,000 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 60,000 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 50,000 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 2,792,826 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 120,000 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 382,000 sh |
Griffiths Richard Ian 10%+ Owner Aug 10, 2026 | SELL | 470,820 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Oct 19, 2026 | Resumption Scheduled | Resumed |
SecBot reports
15 filings · 4 bullish · 1 bearish · 1 mixed · 9 neutral- NEUTRAL SC 13G/ANov 16, 2026
TCG Crossover GP I, LLC and affiliated entities filed an amended Schedule 13G disclosing a 3.9% passive stake in Silence Therapeutics plc as of September 30, 2026, down from 4.6% in the prior filing. The reduction continues a trend of passive investor trimming ahead of the pending Merck KGaA…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 12, 2026
Invus Global Management and affiliated entities filed an amended Schedule 13G disclosing a 4.6%…
The reduction below 5% removes the requirement for future 13G filings by Invus, but the passive nature and small decrease suggest no strategic shift. Monitor for any further selling ahead of the…
- NEUTRAL DEFA14ANov 12, 2026
Silence Therapeutics reported Q3 2026 results showing a reduced net loss of $12.4M ($0.08/share)…
The pending acquisition by Merck KGaA is the dominant corporate event; monitor shareholder vote and regulatory approvals for closing in Q1 2027. The Q3 results are largely backward-looking and…
- NEUTRAL 8-KNov 12, 2026
Silence Therapeutics reported Q3 2026 net loss of $12.4 million ($0.08 per share), narrower than…
The acquisition by Merck KGaA is the primary catalyst; monitor for shareholder vote and regulatory approvals in Q1 2027. The Q3 results are largely backward-looking and overshadowed by the deal.
All SLN filing & press-release reports (15)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 12, 2026
- DEFA14A reportNov 12, 2026
- 8-K reportNov 12, 2026
- SC 13G reportNov 5, 2026
- DEFA14A reportOct 19, 2026
- DEFA14A reportOct 19, 2026
- 8-K reportOct 19, 2026
- SC 13G/A reportOct 13, 2026
- SC 13G reportOct 13, 2026
- 424B5 reportAug 10, 2026
- 8-K reportAug 10, 2026
- 8-K reportAug 10, 2026
- 8-K reportJun 23, 2026
- 8-K reportMar 5, 2026